Frank Mottola, SVP and Chief Technology Operations Officer of Supernus, Inc., filed a Form 4 on November 4, 2026, disclosing changes in beneficial ownership of common stock and equity awards resulting from a merger that became effective on November 2, 2026.

Key Highlights

  • Merger effective date: Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, Inc. on November 2, 2026, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior Pharmaceuticals, Inc.
  • Name change: In connection with the merger, Indivior Pharmaceuticals, Inc. changed its name to "Supernus, Inc."
  • Exchange ratio: Each share of Supernus Pharmaceuticals common stock was cancelled and converted into the right to receive 1.5401 shares of Supernus, Inc. common stock.
  • Common stock reported: Following the merger conversion, Mottola directly holds 30,099 shares of Supernus, Inc. common stock, acquired at $0.00 consideration per the merger terms.
  • Equity awards converted: Eight employee stock options and multiple restricted stock unit awards previously held in Supernus Pharmaceuticals were converted into corresponding Supernus, Inc. awards using the 1.5401 exchange ratio.
  • RSU award of 154,010 shares: A restricted stock unit award covering 154,010 shares of Supernus, Inc. common stock was disclosed, vesting in five installments tied to the merger closing and its subsequent anniversaries, according to the filing.

Merger Conversion Restructures Mottola's Equity Holdings at Supernus, Inc.

According to the filing, the transactions reported all occurred on November 2, 2026, the effective date of a merger pursuant to an Agreement and Plan of Merger dated August 1, 2026, among Indivior Pharmaceuticals, Inc., Artemis Merger Sub Inc., and Supernus Pharmaceuticals, Inc. At the effective time, Artemis Merger Sub merged into Supernus Pharmaceuticals, which survived as a wholly-owned subsidiary. Indivior then renamed itself "Supernus, Inc." and now trades on NASDAQ:SUPN.

The filing states that Mottola's previously held shares of Supernus Pharmaceuticals common stock were disposed of, and shares of Supernus, Inc. common stock were acquired in exchange at the 1.5401 conversion ratio, with no cash consideration other than cash in lieu of a fractional share. The transaction code used for the common stock in Table I is "J," indicating a transaction that is not an open-market purchase or sale but rather one arising from a legal arrangement such as a merger.

All outstanding Supernus Pharmaceuticals equity awards held by Mottola were assumed by Supernus, Inc. and converted into corresponding awards covering the number of Supernus, Inc. shares equal to the original share count multiplied by 1.5401 (rounded down), with per-share exercise prices divided by that ratio and rounded up to the nearest whole cent, as described in the filing. The filing notes that each converted award remains subject to substantially the same terms and conditions, including vesting schedules, except that performance stock unit awards were converted into time-vesting restricted stock units. Among the disclosed RSU awards is one covering 154,010 shares, which the filing states vests 40% at the closing of the merger and 15% at each of the first four anniversaries of the closing.

What Was Disclosed

The Form 4 filed by Frank Mottola, SVP and Chief Technology Operations Officer of Supernus, Inc. (NASDAQ:SUPN), disclosed the conversion of his Supernus Pharmaceuticals equity holdings into Supernus, Inc. securities following the November 2, 2026 merger effective date, with no cash paid for the exchange.